Tumor lysis syndrome pathophysiology: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tumor lysis syndrome}} | {{Tumor lysis syndrome}} | ||
{{CMG}} | {{CMG}} {{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
Development of tumor lysis syndrome is the result of initiation of chemotherapy or radiotherapy in cancer patients. | |||
==Pathophysiology== | ==Pathophysiology== | ||
In [[medicine]] ([[oncology]] and [[hematology]]), '''tumor lysis syndrome''' ('''TLS''') is a group of [[metabolism|metabolic]] complications that can occur after treatment of [[cancer]], usually [[lymphoma]]s and [[leukemia]]s, and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and include [[hyperkalemia]], [[hyperphosphatemia]], [[hyperuricemia]], [[hypocalcemia]], and [[acute renal failure]]. | In [[medicine]] ([[oncology]] and [[hematology]]), '''tumor lysis syndrome''' ('''TLS''') is a group of [[metabolism|metabolic]] complications that can occur after treatment of [[cancer]], usually [[lymphoma]]s and [[leukemia]]s, and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and include [[hyperkalemia]], [[hyperphosphatemia]], [[hyperuricemia]], [[hypocalcemia]], and [[acute renal failure]]. | ||
Revision as of 17:04, 18 September 2015
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome pathophysiology On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome pathophysiology |
|
Risk calculators and risk factors for Tumor lysis syndrome pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Development of tumor lysis syndrome is the result of initiation of chemotherapy or radiotherapy in cancer patients.
Pathophysiology
In medicine (oncology and hematology), tumor lysis syndrome (TLS) is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukemias, and sometimes even without treatment. These complications are caused by the break-down products of dying cancer cells and include hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, and acute renal failure. Pretreatment spontaneous tumor lysis syndrome. This entity is associated with acute renal failure due to uric acid nephropathy prior to the institution of chemotherapy and is largely associated with lymphomas and leukemias. The important distinction between this syndrome and the post-chemotherapy syndrome is that spontaneous TLS is not associated with hyperphosphatemia. One suggestion for the reason of this is that the high cell turnover rate leads to high uric acid levels through nucleoprotein turnover but the tumor reuses the released phosphate for resynthesis of new tumor cells. In post-chemotherapy TLS, tumor cells are destroyed and no new tumor cells are being synthesized.